Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818351 | 0.80 | KCNH2 (0.44) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL25275764 | 0.79 | TRPC5 (0.60) | TRPC5POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL20818730 | 0.78 | ADRB2 (0.42) | TRPC5POLBHTR2AALDH1A1TIPARP | |
| SCHEMBL20818253 | 0.73 | TRPC5 (0.37) | TRPC5POLBIDO1TDO2ALDH1A1 | |
| SCHEMBL17634311 | 0.70 | HTR6 (0.41) | TRPC5LMNATRPV1 | |
| SCHEMBL20817958 | 0.69 | TRPC5 (0.71) | TRPC5KMT2ALMNA | |
| SCHEMBL3723654 | 0.69 | KIT (0.46) | ALDH1A1 | |
| SCHEMBL31073939 | 0.67 | TDO2 (0.54) | IDO1TDO2TRPV1ROCK2CYP3A4 | |
| SCHEMBL209373 | 0.65 | ABL1 (0.39) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL209374 | 0.65 | ABL1 (0.39) | POLBMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885POLB 1701/4885MEN1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.